pmid	doi	year	title	Hugo_Symbol
32771436	10.1016/j.drudis.2020.07.021	2022	Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.	MCL1
33514658	10.1158/1541-7786.MCR-20-0973	2022	Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.	MCL1
33853293	10.3324/haematol.2020.272609	2022	Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.	MCL1
33870156	10.1016/j.jhepr.2021.100250	2022	Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the <i>Mdr2</i> <sup><i>-/-</i></sup>  mouse.	MCL1
34153472	10.1016/j.bmcl.2021.128215	2022	Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.	MCL1
34343635	10.1016/j.canlet.2021.07.045	2022	Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.	MCL1
34601571	10.1182/blood.2021013156	2022	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.	MCL1
34610112	10.1182/bloodadvances.2021004513	2022	Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.	MCL1
34625423	10.1158/0008-5472.CAN-21-1023	2022	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.	MCL1
34728569	10.1158/1535-7163.MCT-21-0511	2022	Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.	MCL1
34913076	10.3892/ijo.2021.5292	2022	Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.	MCL1
35023102	10.1007/978-3-030-78787-5_20	2022	Early and Very Early GRIM19 and MCL1 Expression Are Correlated to Late Acquired Prednisolone Effects in a T-Cell Acute Leukemia Cell Line.	MCL1
35035775	10.18632/oncotarget.28177	2022	GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.	MCL1
35058488	10.1038/s41598-022-04916-6	2022	Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.	MCL1
35136485	10.18632/oncotarget.28189	2022	GZ17-6.02 and axitinib interact to kill renal carcinoma cells.	MCL1
35185150	10.1038/s41392-021-00870-3	2022	Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.	MCL1
35233562	10.15212/amm-2021-0002	2022	The regulation of neuronal autophagy and cell survival by MCL1 in Alzheimer's disease.	MCL1
35704690	10.1182/blood.2021014304	2022	Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.	MCL1
35979721	10.3324/haematol.2022.280631	2022	Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes.	MCL1
30055346	10.1016/j.tranon.2018.07.007	2021	Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression.	MCL1
31501195	10.1101/cshperspect.a035089	2021	Bcl-2-Protein Family as Modulators of IP<sub>3</sub> Receptors and Other Organellar Ca<sup>2+</sup> Channels.	MCL1
31601689	10.3324/haematol.2019.220525	2021	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.	MCL1
32045477	10.1182/bloodadvances.2019000359	2021	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.	MCL1
32126142	10.1182/bloodadvances.2019000844	2021	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.	MCL1
32204955	10.1016/j.blre.2020.100672	2021	Targeting MCL-1 in hematologic malignancies: Rationale and progress.	MCL1
32290241	10.3390/cancers12040938	2021	BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.	MCL1
32385800	10.1007/s12017-020-08600-8	2021	Downregulation of Microrna-421 Relieves Cerebral Ischemia/Reperfusion Injuries: Involvement of Anti-apoptotic and Antioxidant Activities.	MCL1
32397113	10.3390/ijms21093323	2021	Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.	MCL1
32569380	10.1182/bloodadvances.2019001416	2021	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.	MCL1
32600066	10.1080/13543784.2020.1789588	2021	Enhancing venetoclax activity in hematological malignancies.	MCL1
32665700	10.1038/s41375-020-0968-9	2021	Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.	MCL1
32731448	10.3390/biom10081114	2021	Predicted Hotspot Residues Involved in Allosteric Signal Transmission in Pro-Apoptotic Peptide-Mcl1 Complexes.	MCL1
32764384	10.3390/cancers12082182	2021	Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.	MCL1
32860732	10.1002/psp4.12552	2021	Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991.	MCL1
32862872	10.1016/S2152-2650(20)30464-X	2021	Harnessing Apoptosis in AML.	MCL1
32898245	10.1182/bloodadvances.2019001393	2021	AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.	MCL1
32907612	10.1186/s12943-020-01254-x	2021	Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.	MCL1
32943617	10.1038/s41419-020-02944-6	2021	BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.	MCL1
33039369	10.1016/j.humpath.2020.09.016	2021	Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis.	MCL1
33067607	10.1182/blood.2020008017	2021	Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.	MCL1
33125144	10.3892/or.2020.7797	2021	Dracocephalum palmatum Stephan extract induces caspase‑ and mitochondria‑dependent apoptosis via Myc inhibition in diffuse large B cell lymphoma.	MCL1
33205684	10.1080/17474086.2020.1852923	2021	Apoptosis targeted therapies in acute myeloid leukemia: an update.	MCL1
33259592	10.1182/blood.2020008528	2021	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.	MCL1
33298918	10.1038/s41467-020-20136-w	2021	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	MCL1
33446629	10.1038/s41408-020-00402-2	2021	MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.	MCL1
33471866	10.1371/journal.ppat.1009179	2021	Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7.	MCL1
33512431	10.1182/blood.2020007452	2021	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.	MCL1
33560385	10.1182/bloodadvances.2020003429	2021	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.	MCL1
33658484	10.1038/s41419-020-03351-7	2021	Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells.	MCL1
33670870	10.3390/cancers13051002	2021	Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.	MCL1
33735476	10.1002/ajh.26163	2021	R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.	MCL1
33777762	10.3389/fonc.2021.618908	2021	CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> Rearrangements.	MCL1
33803505	10.3390/biology10030234	2021	E3 Ubiquitin Ligase ASB17 Promotes Apoptosis by Ubiquitylating and Degrading BCLW and MCL1.	MCL1
34007050	10.1038/s41375-021-01291-5	2021	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.	MCL1
34061027	10.7554/eLife.67336	2021	Contingency and chance erase necessity in the experimental evolution of ancestral proteins.	MCL1
34088885	10.18632/aging.203098	2021	Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.	MCL1
34339789	10.1016/j.ijbiomac.2021.07.166	2021	Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.	MCL1
34465776	10.1038/s41467-021-25405-w	2021	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.	MCL1
34475520	10.1038/s42003-021-02564-6	2021	The multiple mechanisms of MCL1 in the regulation of cell fate.	MCL1
34576319	10.3390/ijms221810157	2021	BH3 Mimetics in Hematologic Malignancies.	MCL1
34580292	10.1038/s41467-021-25963-z	2021	In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.	MCL1
30224339	10.1158/1078-0432.CCR-18-0867	2020	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.	MCL1
30281155	10.1002/eji.201847585	2020	MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.	MCL1
30523053	10.3324/haematol.2018.204958	2020	Targeting BCL2 with venetoclax is a promising therapeutic strategy for double-proteinexpression lymphoma with <i>MYC</i> and <i>BCL2</i> rearrangements.	MCL1
30538285	10.1038/s41418-018-0244-y	2020	By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737.	MCL1
30601084	10.1080/15384101.2018.1559557	2020	Mitotic slippage: an old tale with a new twist.	MCL1
30626241	10.1080/10428194.2018.1563694	2020	MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.	MCL1
30792387	10.1038/s41419-019-1407-6	2020	BCL-2 family isoforms in apoptosis and cancer.	MCL1
30872780	10.1038/s41375-019-0442-8	2020	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	MCL1
31004002	10.1158/1078-0432.CCR-18-3275	2020	Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal <i>In Vivo</i> in Relapsed Mantle Cell Lymphoma.	MCL1
31117518	10.1021/acs.jmedchem.9b00455	2020	From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).	MCL1
31161836	10.1080/10428194.2019.1622098	2020	Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.	MCL1
31171817	10.1038/s41375-019-0503-z	2020	Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.	MCL1
31243099	10.1158/1535-7163.MCT-18-1023	2020	Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.	MCL1
31349760	10.1080/15384101.2019.1646068	2020	The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.	MCL1
31387206	10.3390/cells8080829	2020	Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-x<sub>L</sub>.	MCL1
31467227	10.21873/cgp.20138	2020	Association of Leukemia Target Genes <i>Tet2, Bcl2</i>, and <i>Slc23a2</i> in Vitamin C Pathways.	MCL1
31533276	10.3390/genes10090718	2020	Allele-Specific Expression of CD4<sup>+</sup> T Cells in Response to Marek's Disease Virus Infection.	MCL1
31543463	10.1016/j.ccell.2019.08.005	2020	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.	MCL1
31692474	10.1107/S2059798319014116	2020	Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1.	MCL1
31740676	10.1038/s41408-019-0249-x	2020	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.	MCL1
31772331	10.1038/s41388-019-1122-x	2020	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.	MCL1
31794606	10.1182/blood.2019001866	2020	Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.	MCL1
31801186	10.3390/ijms20236036	2020	Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.	MCL1
31894587	10.1002/lary.28441	2020	Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma.	MCL1
31971799	10.1021/acs.jmedchem.9b01442	2020	Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins.	MCL1
32014946	10.21873/anticanres.14035	2020	Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer.	MCL1
32245312	10.18502/ijaai.v18i6.2181	2020	Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.	MCL1
32645016	10.1371/journal.pone.0234103	2020	Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.	MCL1
33198338	10.3390/cancers12113353	2020	BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic.	MCL1
33292251	10.1186/s12935-020-01614-z	2020	Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies.	MCL1
27480872	10.1158/1078-0432.CCR-16-1315	2019	Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.	MCL1
28485156	10.4149/neo_2017_404	2019	The Effects of Lentivirus-mediated shRNA Interference Targeting Mcl-1 on Growth of NK/T-cell Lymphoma.	MCL1
28751770	10.1038/leu.2017.243	2019	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.	MCL1
29241222	10.1038/bjc.2017.432	2019	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.	MCL1
29269870	10.1038/s41598-017-18368-w	2019	Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.	MCL1
29348517	10.1038/s41419-017-0184-3	2019	NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio.	MCL1
29352235	10.1038/s41419-017-0039-y	2019	Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.	MCL1
29521234	10.2174/1568009618666180308105048	2019	Noxa: Role in Cancer Pathogenesis and Treatment.	MCL1
29570100	10.1097/CAD.0000000000000616	2019	Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.	MCL1
29716994	10.1074/jbc.RA118.002791	2019	Folding and binding pathways of BH3-only proteins are encoded within their intrinsically disordered sequence, not templated by partner proteins.	MCL1
29740433	10.3389/fimmu.2018.00787	2019	SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production.	MCL1
29799788	10.1096/fj.201800425R	2019	Ursolic acid facilitates apoptosis in rheumatoid arthritis synovial fibroblasts by inducing SP1-mediated Noxa expression and proteasomal degradation of Mcl-1.	MCL1
29941549	10.1084/jem.20170484	2019	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.	MCL1
30008477	10.1038/s41375-018-0201-2	2019	The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.	MCL1
30111820	10.1038/s41467-018-05506-9	2019	Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.	MCL1
30131584	10.1038/s41375-018-0239-1	2019	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.	MCL1
30154155	10.1158/0008-5472.CAN-18-0195	2019	Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.	MCL1
30260324	10.1172/JCI122533	2019	PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.	MCL1
30282833	10.1172/jci.insight.121438	2019	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.	MCL1
30296359	10.1002/iub.1944	2019	MCL1 gene silencing promotes senescence and apoptosis of glioma cells via inhibition of the PI3K/Akt signaling pathway.	MCL1
30404918	10.1073/pnas.1806928115	2019	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.	MCL1
30445933	10.1186/s12885-018-5018-x	2019	Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.	MCL1
30478448	10.1038/s41388-018-0567-7	2019	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.	MCL1
30498064	10.1182/blood-2018-07-865527	2019	Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.	MCL1
30569090	10.3892/mmr.2018.9738	2019	miR‑15a‑3p affects the proliferation, migration and apoptosis of lens epithelial cells.	MCL1
30639456	10.1016/j.bcp.2019.01.009	2019	miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.	MCL1
30663221	10.1002/1878-0261.12454	2019	The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.	MCL1
30733202	10.1182/blood-2018-12-889741	2019	Functional profiling to improve therapy in TCL.	MCL1
31215288	10.1080/10799893.2019.1625062	2019	Phytosterols and triterpenes from <i>Morinda lucida</i> Benth (<i>Rubiaceae</i>) as potential inhibitors of anti-apoptotic BCL-XL, BCL-2, and MCL-1: an in-silico study.	MCL1
31566022	10.1080/13543776.2019.1672661	2019	MCL-1 inhibitors - where are we now (2019)?	MCL1
25914292	10.1002/hed.24096	2018	Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia-1.	MCL1
27479816	10.3324/haematol.2016.142323	2018	Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA.	MCL1
27752131	10.1038/srep35349	2018	TRAF3 deficiency promotes metabolic reprogramming in B cells.	MCL1
28134252	10.1038/ncomms14290	2018	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.	MCL1
28140720	10.1080/10428194.2017.1283032	2018	Pathways and mechanisms of venetoclax resistance.	MCL1
28396094	10.1016/j.phrs.2017.04.006	2018	YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.	MCL1
28445949	10.18632/oncotarget.15600	2018	LMP1+SLAMF1high cells are associated with drug resistance in Epstein-Barr virus-positive Farage cells.	MCL1
28447716	10.3892/mmr.2017.6303	2018	PAR1‑mediated c‑Jun activation promotes heat stress‑induced early stage apoptosis of human umbilical vein endothelial cells.	MCL1
28537899	10.18632/oncotarget.17669	2018	NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.	MCL1
28578655	10.1186/s12885-017-3383-5	2018	Potential mechanisms of resistance to venetoclax and strategies to circumvent it.	MCL1
28797244	10.1186/s12885-017-3530-z	2018	A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.	MCL1
28855351	10.1158/1078-0432.CCR-17-1144	2018	Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.	MCL1
28885268	10.1097/CAD.0000000000000550	2018	N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation.	MCL1
29275301	10.21873/invivo.11206	2018	Cycloartobiloxanthone Induces Human Lung Cancer Cell Apoptosis <i>via</i> Mitochondria-dependent Apoptotic Pathway.	MCL1
29318382	10.1007/s00432-017-2575-3	2018	MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.	MCL1
29361709	10.3390/ijms19010308	2018	Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members.	MCL1
29407973	10.1016/j.ejmech.2018.01.076	2018	Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.	MCL1
29567880	10.4103/IJPM.IJPM_731_16	2018	Myeloid cell leukemia-1 protein expression and myeloid cell leukemia-1 gene amplification in non small cell lung cancer.	MCL1
29845223	10.3892/mmr.2018.9035	2018	Apoptosis induced by 9,11‑dehydroergosterol peroxide from Ganoderma Lucidum mycelium in human malignant melanoma cells is Mcl‑1 dependent.	MCL1
29901068	10.3892/ijo.2018.4427	2018	Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.	MCL1
30251692	10.1016/j.bbadis.2018.09.010	2018	Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.	MCL1
30396948	10.21873/anticanres.12984	2018	Phoyunnanin E Induces Apoptosis of Non-small Cell Lung Cancer Cells <i>via</i> p53 Activation and Down-regulation of Survivin.	MCL1
26939705	10.1158/1535-7163.MCT-15-0828	2017	Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.	MCL1
27022142	10.1177/1535370216640944	2017	Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.	MCL1
27023223	10.1007/s12035-016-9842-1	2017	An Antagomir to MicroRNA-106b-5p Ameliorates Cerebral Ischemia and Reperfusion Injury in Rats Via Inhibiting Apoptosis and Oxidative Stress.	MCL1
27055871	10.1038/leu.2016.49	2017	Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.	MCL1
27056887	10.18632/oncotarget.8547	2017	High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.	MCL1
27159593	10.1002/art.39744	2017	Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.	MCL1
27176505	10.3892/ijo.2016.3518	2017	The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.	MCL1
27431074	10.3760/cma.j.issn.0253-2727.2016.06.010	2017	[Clinical analysis of the character and prognostic factors of 23 cases of mantle cell lymphoma].	MCL1
27479182	10.1038/leu.2016.213	2017	Survival control of malignant lymphocytes by anti-apoptotic MCL-1.	MCL1
27569395	10.1038/aps.2016.49	2017	Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.	MCL1
27582059	10.1126/scitranslmed.aaf5309	2017	Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.	MCL1
27744724	10.1080/13543776.2017.1249848	2017	Mcl-1 inhibitors: a patent review.	MCL1
27748795	10.3892/ijo.2016.3729	2017	B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway.	MCL1
27760111	10.1038/nature19830	2017	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.	MCL1
27907212	10.1371/journal.pone.0167599	2017	Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.	MCL1
27919953	10.21873/anticanres.11229	2017	Bishydroquinone Renieramycin M Induces Apoptosis of Human Lung Cancer Cells Through a Mitochondria-dependent Pathway.	MCL1
27974663	10.1126/scitranslmed.aae0348	2017	PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.	MCL1
27997540	10.1371/journal.pmed.1002200	2017	IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.	MCL1
28057804	10.1084/jem.20160869	2017	Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival.	MCL1
28104700	10.3324/haematol.2016.159160	2017	Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.	MCL1
28154184	10.1074/jbc.M116.754184	2017	Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.	MCL1
28190086	10.1007/s00441-017-2576-1	2017	MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.	MCL1
28192408	10.1038/onc.2016.515	2017	Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.	MCL1
28209992	10.1038/nrd.2016.253	2017	From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.	MCL1
28295185	10.1111/bjh.14571	2017	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.	MCL1
28368400	10.1038/onc.2017.85	2017	Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.	MCL1
28411240	10.1074/jbc.M116.768879	2017	Structural basis of apoptosis inhibition by the fowlpox virus protein FPV039.	MCL1
28449207	10.1111/bjh.14684	2017	Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.	MCL1
28467689	10.1002/mc.22672	2017	Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.	MCL1
28504646	10.1172/JCI80631	2017	The RNA-binding protein tristetraprolin schedules apoptosis of pathogen-engaged neutrophils during bacterial infection.	MCL1
28522751	10.1158/0008-5472.CAN-16-3470	2017	Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.	MCL1
28670929	10.1080/14728222.2017.1349754	2017	Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.	MCL1
29061914	10.1042/BCJ20170080	2017	Therapeutics targeting Bcl-2 in hematological malignancies.	MCL1
24828872	10.3109/10428194.2014.922180	2016	Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.	MCL1
25388617	10.1007/s00109-014-1221-7	2016	BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.	MCL1
25649768	10.1158/0008-5472.CAN-14-1849	2016	BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.	MCL1
25715028	10.1080/15548627.2015.1017191	2016	BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.	MCL1
25781640	10.1371/journal.pone.0120334	2016	REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.	MCL1
25797245	10.18632/oncotarget.3275	2016	Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.	MCL1
25815462	10.3892/mmr.2015.3534	2016	Apoptosis of HL-60 human leukemia cells induced by Asiatic acid through modulation of B-cell lymphoma 2 family proteins and the mitogen-activated protein kinase signaling pathway.	MCL1
25818766	10.1016/j.bmc.2015.03.024	2016	Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.	MCL1
25950485	10.1038/cddis.2015.95	2016	Mcl-1 is a key regulator of the ovarian reserve.	MCL1
26043155	10.1080/15548627.2015.1055439	2016	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	MCL1
26045046	10.1038/cdd.2015.73	2016	Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.	MCL1
26110568	10.18632/oncotarget.4230	2016	Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.	MCL1
26134786	10.1186/s12943-015-0397-y	2016	Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.	MCL1
26178811	10.1002/cbf.3121	2016	Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.	MCL1
26231047	10.1186/s12885-015-1582-5	2016	Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.	MCL1
26251039	10.1111/cas.12766	2016	Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.	MCL1
26252798	10.3892/mmr.2015.4186	2016	Momordica cochinchinensis Spreng. seed extract suppresses breast cancer growth by inducing cell cycle arrest and apoptosis.	MCL1
26255115	10.1016/j.biocel.2015.08.002	2016	Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-α.	MCL1
26338963	10.18632/oncotarget.4911	2016	Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression.	MCL1
26352605	10.3892/mmr.2015.4299	2016	ApoG2 inhibits the antiapoptotic protein, Mcl‑1, and induces mitochondria‑dependent apoptosis in human colorectal cancer cells.	MCL1
26392332	10.18632/oncotarget.5156	2016	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.	MCL1
26431330	10.18632/oncotarget.5901	2016	Subcellular localization of PUMA regulates its pro-apoptotic activity in Burkitt's lymphoma B cells.	MCL1
26460954	10.18632/oncotarget.6051	2016	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.	MCL1
26467384	10.1158/1078-0432.CCR-15-1191	2016	Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.	MCL1
26485504	10.1016/j.ejphar.2015.10.027	2016	Baicalin inhibiting cerebral ischemia/hypoxia-induced neuronal apoptosis via MRTF-A-mediated transactivity.	MCL1
26538029	10.1091/mbc.E15-01-0028	2016	Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death.	MCL1
26565405	10.1038/bcj.2015.88	2016	Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).	MCL1
26610208	10.1038/cddis.2015.341	2016	In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.	MCL1
26670606	10.1074/jbc.M115.672873	2016	Leishmania donovani Exploits Myeloid Cell Leukemia 1 (MCL-1) Protein to Prevent Mitochondria-dependent Host Cell Apoptosis.	MCL1
26755589	10.1073/pnas.1514586113	2016	Nuclear TRAF3 is a negative regulator of CREB in B cells.	MCL1
26935754	10.3892/mmr.2016.4967	2016	Apoptosis is induced by shikonin through the mitochondrial signaling pathway.	MCL1
26947081	10.1016/j.celrep.2016.02.039	2016	Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.	MCL1
26962682	10.1038/cddis.2016.43	2016	Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.	MCL1
27069144		2016	Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis.	MCL1
24013721	10.1038/cdd.2013.123	2015	The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.	MCL1
24213575	10.1038/onc.2013.469	2015	Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation.	MCL1
24637636	10.1158/1078-0432.CCR-13-2305	2015	COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.	MCL1
24939844	10.1074/jbc.M114.587873	2015	Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.	MCL1
24952874	10.18632/oncotarget.2054	2015	RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.	MCL1
25013123	10.1158/1078-0432.CCR-14-0259	2015	Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.	MCL1
25070836	10.1158/1078-0432.CCR-14-0034	2015	PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.	MCL1
25096574	10.1074/jbc.M114.569632	2015	B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.	MCL1
25122609	10.1182/blood-2014-03-559385	2015	Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.	MCL1
25139387	10.1038/srep06098	2015	Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.	MCL1
25270224	10.3892/ijmm.2014.1949	2015	Tanshinone IIA inhibits human gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl‑1 and Bcl‑xL and increasing Bax and CHOP protein expression.	MCL1
25368374	10.1182/blood-2014-09-601567	2015	MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.	MCL1
25465126	10.1016/j.leukres.2014.10.009	2015	Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.	MCL1
25535978	10.1097/CAD.0000000000000200	2015	The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.	MCL1
25541152	10.1038/leu.2014.351	2015	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.	MCL1
25559680	10.1111/febs.13188	2015	Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.	MCL1
25576220	10.1016/j.gene.2015.01.001	2015	MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.	MCL1
25578475	10.1038/leu.2015.10	2015	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.	MCL1
25590803	10.1038/cddis.2014.525	2015	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.	MCL1
25605735	10.1074/jbc.M114.631564	2015	Mouse cytotoxic T cell-derived granzyme B activates the mitochondrial cell death pathway in a Bim-dependent fashion.	MCL1
25642772	10.1172/JCI75821	2015	Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.	MCL1
25735983	10.1016/j.bbrc.2015.02.115	2015	Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.	MCL1
25756510	10.1080/15384047.2014.1002333	2015	EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.	MCL1
25789974	10.1038/cddis.2015.65	2015	Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.	MCL1
25814533	10.1182/blood-2014-10-605584	2015	Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.	MCL1
25847014	10.1182/blood-2015-01-621250	2015	Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress.	MCL1
25882699	10.1038/leu.2015.99	2015	Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.	MCL1
25987560	10.1074/jbc.M114.602193	2015	Minimalist Model Systems Reveal Similarities and Differences between Membrane Interaction Modes of MCL1 and BAK.	MCL1
26014377	10.1002/ptr.5371	2015	Inhibition of Myeloid Cell Leukemia 1 and Activation of Caspases Are Critically Involved in Gallotannin-induced Apoptosis in Prostate Cancer Cells.	MCL1
26116531	10.1016/j.bbrc.2015.06.120	2015	Niclosamide, an anti-helminthic molecule, downregulates the retroviral oncoprotein Tax and pro-survival Bcl-2 proteins in HTLV-1-transformed T lymphocytes.	MCL1
26184999	10.1016/j.canlet.2015.07.006	2015	Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and Mcl-1 in PEL cells.	MCL1
22999885	10.1016/j.chembiol.2012.07.018	2014	A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.	MCL1
23680845	10.4161/auto.24817	2014	Sh3glb1/Bif-1 and mitophagy: acquisition of apoptosis resistance during Myc-driven lymphomagenesis.	MCL1
23721513	10.3109/10428194.2013.806800	2014	Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.	MCL1
23828564	10.1038/cddis.2013.236	2014	Endoplasmic reticulum stress sensitizes pancreatic beta cells to interleukin-1β-induced apoptosis via Bim/A1 imbalance.	MCL1
23908358	10.1158/1078-0432.CCR-13-1215	2014	Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.	MCL1
23936317	10.1371/journal.pone.0069126	2014	Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.	MCL1
24030073	10.1038/bjc.2013.562	2014	MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways.	MCL1
24038028	10.3324/haematol.2013.085340	2014	Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia.	MCL1
24124106	10.1002/cmdc.201300316	2014	De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.	MCL1
24140475	10.1016/j.cellsig.2013.09.021	2014	New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.	MCL1
24142999	10.3324/haematol.2013.093823	2014	The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance.	MCL1
24356997	10.3892/ijmm.2013.1595	2014	UVB-induced anti-survival and pro-apoptotic effects on HaCaT human keratinocytes via caspase- and PKC-dependent downregulation of PKB, HIAP-1, Mcl-1, XIAP and ER stress.	MCL1
24363325	10.1073/pnas.1321259110	2014	Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.	MCL1
24703900	10.1016/j.ejca.2014.03.011	2014	Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.	MCL1
24778183	10.1074/jbc.M114.562900	2014	Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.	MCL1
24912196	10.1073/pnas.1406425111	2014	Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak.	MCL1
24989909		2014	[Effect of downregulation of Tiam1 by siRNA on esophageal squamous cell carcinoma EC9706 cells].	MCL1
25088254	10.1016/j.yexcr.2014.07.024	2014	BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.	MCL1
22411899	10.1158/1535-7163.MCT-12-0021	2013	Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.	MCL1
22653339	10.1038/cdd.2012.67	2013	C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in β-cells.	MCL1
22848414	10.1371/journal.pone.0040934	2013	IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia.	MCL1
22955922	10.1182/blood-2012-02-412643	2013	Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.	MCL1
23056582	10.1371/journal.pone.0047060	2013	Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer.	MCL1
23091298	10.1182/blood-2012-06-437624	2013	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.	MCL1
23181473	10.3109/10428194.2012.752485	2013	Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.	MCL1
23225436		2013	Artonin E mediates MCL1 down-regulation and sensitizes lung cancer cells to anoikis.	MCL1
23231952	10.1158/1078-0432.CCR-12-1935	2013	Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.	MCL1
23236068	10.1128/JVI.01393-12	2013	Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation.	MCL1
23257783	10.1038/leu.2012.367	2013	MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.	MCL1
23360303	10.1111/bjh.12206	2013	The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.	MCL1
23393342		2013	Ecteinascidin 770, a tetrahydroisoquinoline alkaloid, sensitizes human lung cancer cells to anoikis.	MCL1
23440244	10.1182/blood-2012-06-434365	2013	RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.	MCL1
23484699	10.7534/j.issn.1009-2137.2013.01.020	2013	[Expression of MCL-1 and microRNA-29a in extranodal NK/T-cell lymphoma tissue].	MCL1
23580240	10.1002/ijc.28206	2013	Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.	MCL1
23633928	10.1593/neo.13230	2013	Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis.	MCL1
23966420	10.1182/blood-2013-01-478651	2013	Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.	MCL1
23986435	10.1074/jbc.M112.443093	2013	The Bcl-2 homology domain 3 (BH3)-only proteins Bim and bid are functionally active and restrained by anti-apoptotic Bcl-2 family proteins in healthy liver.	MCL1
21660046	10.1038/cdd.2011.69	2012	Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa.	MCL1
21863213	10.2119/molmed.2011.00176	2012	The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.	MCL1
21975296	10.1038/cddis.2011.95	2012	Cytokine-dependent and cytokine-independent roles for Mcl-1: genetic evidence for multiple mechanisms by which Mcl-1 promotes survival in primary T lymphocytes.	MCL1
21997189	10.1038/cdd.2011.133	2012	Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.	MCL1
22064518	10.4161/cc.10.22.18288	2012	Targeted cancer therapy: what if the driver is just a messenger?	MCL1
22071632	10.1038/cddis.2011.109	2012	Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.	MCL1
22159912	10.1007/s00125-011-2399-7	2012	Involvement of the RNA-binding protein ARE/poly(U)-binding factor 1 (AUF1) in the cytotoxic effects of proinflammatory cytokines on pancreatic beta cells.	MCL1
22173547	10.1158/1078-0432.CCR-11-1166	2012	Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.	MCL1
22185779	10.4161/cc.11.1.18408	2012	Inhibiting mitochondrial-dependent proteolysis of Mcl-1 promotes resistance to DNA damage.	MCL1
22190165	10.1002/ajh.22263	2012	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.	MCL1
22219388	10.1124/mol.111.076851	2012	Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.	MCL1
22268450	10.3109/10428194.2012.659736	2012	Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.	MCL1
22465296	10.1016/j.exphem.2012.03.002	2012	Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines.	MCL1
22936798	10.1074/jbc.M112.373746	2012	The endoplasmic reticulum stress transducer BBF2H7 suppresses apoptosis by activating the ATF5-MCL1 pathway in growth plate cartilage.	MCL1
19968719	10.1111/j.1751-553X.2009.01204.x	2011	Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.	MCL1
21132008	10.1038/onc.2010.559	2011	Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines.	MCL1
21139584	10.1038/sj.bjc.6606007	2011	Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.	MCL1
21235240	10.1021/jm101181u	2011	3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies.	MCL1
21368833	10.1038/nature09732	2011	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	MCL1
21454712	10.1074/jbc.M110.189092	2011	Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.	MCL1
21471522	10.1182/blood-2010-09-301994	2011	MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.	MCL1
21649540	10.3109/10428194.2011.569962	2011	Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.	MCL1
21670080	10.1158/0008-5472.CAN-10-4531	2011	Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.	MCL1
21844565	10.1182/blood-2011-04-351072	2011	SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.	MCL1
21859846	10.1084/jem.20110846	2011	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.	MCL1
21868573	10.1182/blood-2011-04-347096	2011	Regulation of memory B-cell survival by the BH3-only protein Puma.	MCL1
21868575	10.1182/blood-2011-04-345181	2011	A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.	MCL1
19369968	10.1038/gt.2009.39	2010	VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.	MCL1
19498445	10.1038/cdd.2009.69	2010	miR-15a and miR-16-1 in cancer: discovery, function and future perspectives.	MCL1
19676043	10.1002/ijc.24823	2010	Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG.	MCL1
19684859	10.1371/journal.pone.0006651	2010	RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.	MCL1
19948485	10.1083/jcb.200904049	2010	MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts.	MCL1
19965632	10.1182/blood-2009-02-205963	2010	Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.	MCL1
19968497	10.3109/07357900903095714	2010	Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C&gt;T, BCL2-938C&gt;A, MCL1-386C&gt;G) in extrahepatic cholangiocarcinoma.	MCL1
20004446	10.1016/j.surg.2009.10.033	2010	Adenovirus-mediated siRNA targeting Mcl-1 gene increases radiosensitivity of pancreatic carcinoma cells in vitro and in vivo.	MCL1
20197552	10.1182/blood-2009-07-233304	2010	Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.	MCL1
20200450	10.1172/JCI39987	2010	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.	MCL1
20201946	10.1111/j.1365-2141.2010.08123.x	2010	High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.	MCL1
20227268	10.1016/j.coi.2010.02.004	2010	STAT5 in B cell development and leukemia.	MCL1
20631380	10.1182/blood-2010-04-281071	2010	Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.	MCL1
20799354	10.1002/hep.23836	2010	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.	MCL1
20836993	10.1016/j.bcp.2010.09.002	2010	Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis.	MCL1
20956547	10.1084/jem.20091962	2010	Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.	MCL1
18552129	10.1677/JME-08-0010	2009	Triiodothyronine utilizes phosphatidylinositol 3-kinase pathway to activate anti-apoptotic myeloid cell leukemia-1.	MCL1
19020783		2009	Transcription of genes of p53-dependent apoptosis in acute leukaemia.	MCL1
19092849	10.1038/leu.2008.346	2009	Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.	MCL1
19137012	10.1038/onc.2008.466	2009	MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family.	MCL1
19190247	10.1182/blood-2008-09-175430	2009	The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.	MCL1
19372563	10.1158/1535-7163.MCT-08-1050	2009	Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins.	MCL1
19412536	10.1371/journal.pone.0005428	2009	Altering chemosensitivity by modulating translation elongation.	MCL1
19481066	10.1016/j.bcp.2009.05.025	2009	Bz-423 superoxide signals B cell apoptosis via Mcl-1, Bak, and Bax.	MCL1
19571464	10.1254/jphs.08339fp	2009	Role of myeloid cell leukemia-1 in cell growth of squamous cell carcinoma.	MCL1
17761520	10.1182/blood-2006-10-053884	2008	FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.	MCL1
18032706	10.1182/blood-2007-09-110601	2008	Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways.	MCL1
18055695	10.1101/gad.1604407	2008	Dissecting eIF4E action in tumorigenesis.	MCL1
18275607	10.1186/1476-4598-7-20	2008	Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.	MCL1
18349030	10.1093/annonc/mdn056	2008	Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model.	MCL1
18589438	10.1016/j.jmb.2008.05.071	2008	Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1.	MCL1
18664580	10.1073/pnas.0804821105	2008	mTORC1 promotes survival through translational control of Mcl-1.	MCL1
18689543	10.1182/blood-2007-11-124487	2008	Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.	MCL1
16949642	10.1016/j.humpath.2006.06.017	2007	Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas.	MCL1
17097560	10.1016/j.ccr.2006.10.006	2007	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.	MCL1
17097561	10.1016/j.ccr.2006.08.027	2007	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.	MCL1
17116485	10.1016/j.cancergencyto.2006.04.019	2007	Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08.	MCL1
17200714	10.1172/JCI28281	2007	Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.	MCL1
17227835	10.1182/blood-2006-07-034173	2007	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.	MCL1
18025305	10.1083/jcb.200703040	2007	Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis.	MCL1
16189266	10.1182/blood-2005-07-2930	2006	The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.	MCL1
16382050	10.1196/annals.1339.047	2006	Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.	MCL1
16763612	10.1038/modpathol.3800632	2006	Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma.	MCL1
17010674	10.1016/j.ccr.2006.09.006	2006	Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.	MCL1
15370246	10.1080/10428190410001723317	2005	Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.	MCL1
15550399	10.1074/jbc.M411434200	2005	Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands.	MCL1
15613543	10.1182/blood-2004-10-3984	2005	Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis.	MCL1
15718423	10.1182/blood-2004-05-1699	2005	Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.	MCL1
15897243	10.1158/1535-7163.MCT-04-0330	2005	Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.	MCL1
15905648	10.1159/000084213	2005	Positional and functional characterisation of apoptosis related genes belonging to the BCL2 family in sheep.	MCL1
16007205	10.1038/sj.onc.1208751	2005	Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model.	MCL1
15122313	10.1038/sj.onc.1207648	2004	Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.	MCL1
15126604	10.1093/jnci/djh122	2004	Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.	MCL1
15240948	10.1292/jvms.66.709	2004	Molecular cloning of canine Mcl-1 gene and its expression in tumor cell lines.	MCL1
12580957	10.1046/j.1365-2141.2003.04121.x	2003	Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma.	MCL1
11830549		2002	An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.	MCL1
11841410	10.1046/j.1365-2141.2002.03253.x	2002	High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma.	MCL1
12057933	10.1016/S0002-9440(10)61178-9	2002	Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors.	MCL1
10978339	10.1074/jbc.M006626200	2001	Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen.	MCL1
11389033	10.1182/blood.v97.12.3902	2001	MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes.	MCL1
10637245	10.1200/JCO.2000.18.2.317	2000	European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.	MCL1
10697273	10.1038/modpathol.3880030	2000	Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients.	MCL1
10707792		2000	Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.	MCL1
10777489	10.1074/jbc.M000915200	2000	Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition.	MCL1
10090728	10.1101/gad.13.6.718	1999	Role of Nr13 in regulation of programmed cell death in the bursa of Fabricius.	MCL1
8587122	10.1007/BF00173157	1996	Molecular evolution and secondary structural conservation in the B-cell lymphoma leukemia 2 (bcl-2) family of proto-oncogene products.	MCL1
7835896	10.1006/geno.1994.1523	1995	Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease.	MCL1
